核苷与核苷酸。100. 2'-C-氰基-2'-脱氧-1-β-D-阿拉伯呋喃糖基胞嘧啶（CNDAC）：一种基于潜在机制的DNA链断裂抗肿瘤核苷的设计 - Suppr

Suppr

超能文献

Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.

作者信息

Matsuda A, Nakajima Y, Azuma A, Tanaka M, Sasaki T

机构信息

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

出版信息

J Med Chem. 1991 Sep;34(9):2917-9. doi: 10.1021/jm00113a034.

DOI:10.1021/jm00113a034

PMID:1895307

Abstract

摘要

相似文献

Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.核苷与核苷酸。100. 2'-C-氰基-2'-脱氧-1-β-D-阿拉伯呋喃糖基胞嘧啶（CNDAC）：一种基于潜在机制的DNA链断裂抗肿瘤核苷的设计

J Med Chem. 1991 Sep;34(9):2917-9. doi: 10.1021/jm00113a034.

Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.核苷与核苷酸。141. 一种新型抗肿瘤核苷2'-C-氰基-2'-脱氧-1-β-D-阿拉伯呋喃糖基胞嘧啶在碱性介质中的化学稳定性：2'-C-氰基-2'-脱氧-1-β-D-核糖呋喃糖基胞嘧啶的形成及其抗肿瘤活性。

J Med Chem. 1995 Aug 18;38(17):3391-7. doi: 10.1021/jm00017a023.

Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).CNDAC（1-(2-C-氰基-2-脱氧-β-D-阿拉伯呋喃糖基)胞嘧啶）及其N4-棕榈酰衍生物（CS-682）的抗肿瘤活性和新型DNA自链断裂机制

Int J Cancer. 1999 Jul 19;82(2):226-36. doi: 10.1002/(sici)1097-0215(19990719)82:2<226::aid-ijc13>3.0.co;2-x.

Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors.

Cancer Lett. 1992 May 30;64(1):67-74. doi: 10.1016/0304-3835(92)90024-p.

Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.

J Med Chem. 1993 Dec 24;36(26):4183-9. doi: 10.1021/jm00078a006.

[Design of a new antitumor nucleoside CNDAC, against solid tumors].

Gan To Kagaku Ryoho. 1996 Jan;23(2):202-10.

Antitumor activity of a novel orally effective nucleoside, 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine.一种新型口服有效的核苷1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)胞嘧啶的抗肿瘤活性

Cancer Lett. 1998 Jul 3;129(1):103-10. doi: 10.1016/s0304-3835(98)00089-5.

Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.基于机制的与DNA链断裂核苷类似物CNDAC的药物组合

Mol Cancer Ther. 2016 Oct;15(10):2302-2313. doi: 10.1158/1535-7163.MCT-15-0801. Epub 2016 Jul 29.

Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).脱氧胞苷类似物2'-C-氰基-2'-脱氧-1-β-D-阿拉伯呋喃糖基胞嘧啶（CNDAC）的细胞药代动力学和药效学

Biochem Pharmacol. 2001 Jun 15;61(12):1497-507. doi: 10.1016/s0006-2952(01)00617-7.

2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.2'-C-氰基-2'-脱氧-1-β-D-阿拉伯呋喃糖基胞嘧啶：一种新型抗癌核苷类似物，可导致DNA链断裂和G(2)期阻滞。

Mol Pharmacol. 2001 Apr;59(4):725-31. doi: 10.1124/mol.59.4.725.

引用本文的文献

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).随机 3 期研究口服 sapacitabine 在新诊断为急性髓细胞白血病的老年患者中的结果 (SEAMLESS)。

Cancer. 2021 Dec 1;127(23):4421-4431. doi: 10.1002/cncr.33828. Epub 2021 Aug 23.

CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death.CNDAC 诱导的 DNA 双链断裂导致细胞死亡前的异常有丝分裂。

Mol Cancer Ther. 2019 Dec;18(12):2283-2295. doi: 10.1158/1535-7163.MCT-18-1380. Epub 2019 Sep 9.

The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.抗病毒核苷类似物的进化：化学家和非化学家的综述。第二部分：核苷骨架的复杂修饰。

Antiviral Res. 2019 Feb;162:5-21. doi: 10.1016/j.antiviral.2018.11.016. Epub 2018 Dec 8.

Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.个体复制叉的超分辨成像揭示了出乎意料的前药耐药机制。

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1366-E1373. doi: 10.1073/pnas.1714790115. Epub 2018 Jan 29.

Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs.抗癌核苷、核苷酸及碱基类似物的代谢、生化作用和化学合成

Chem Rev. 2016 Dec 14;116(23):14379-14455. doi: 10.1021/acs.chemrev.6b00209. Epub 2016 Nov 23.

New drugs in acute myeloid leukemia.急性髓系白血病的新药

Ann Oncol. 2016 May;27(5):770-8. doi: 10.1093/annonc/mdw015. Epub 2016 Jan 22.

Chronic myelomonocytic leukemia: Forefront of the field in 2015.慢性粒单核细胞白血病：2015年该领域的前沿

Crit Rev Oncol Hematol. 2015 Aug;95(2):222-42. doi: 10.1016/j.critrevonc.2015.03.002. Epub 2015 Mar 14.

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.新型核苷类似物萨帕他滨与小剂量阿糖胞苷治疗老年急性髓系白血病的随机比较。

Leukemia. 2015 Jun;29(6):1312-9. doi: 10.1038/leu.2015.38. Epub 2015 Feb 13.

Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.沙帕他滨简介：在老年新发急性髓系白血病患者中的治疗潜力。

Clin Interv Aging. 2014 May 6;9:753-62. doi: 10.2147/CIA.S39558. eCollection 2014.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.口服萨卡替比用于治疗老年急性髓系白血病的随机 2 期研究。

Lancet Oncol. 2012 Nov;13(11):1096-104. doi: 10.1016/S1470-2045(12)70436-9. Epub 2012 Oct 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验